NCT06798558 - Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions

Prostate Adenocarcinoma

Interventions

DRUG

Lu-17-PSMA-617

Lu-17-PSMA-617 administration

Trial Locations (3)

NOT_YET_RECRUITING

MedStar Washington Hospital Center, Washington D.C.

NOT_YET_RECRUITING

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack